Etanercept is indicated for the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It acts as a tumor necrosis factor (TNF) inhibitor, binding and neutralizing TNF-alpha, a key mediator of inflammation. Its main advantage is targeted and rapid reduction of inflammation, leading to relief of pain, swelling, and stiffness, as well as slowing disease progression and joint damage. Etanercept has a well-established safety and efficacy profile and is widely used in patients who do not respond adequately to conventional therapies. Subcutaneous administration allows convenient outpatient use, while providing consistent and predictable clinical outcomes. It plays an important role in long-term disease control and improving quality of life.